Increasing patients’ safety and care in research is vital when preparing and conducting your study. From a HEMEX perspective, we are tackling in this article four important points you should consider during the process.
Hemex Team Press Release
HEMEX opens subsidiary in Belgium, expanding its presence in the EU
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Clinical Development Innovation Press Release
hemotune AG Achieves ISO 13485 Certification, Advancing Breakthrough Nanotechnology in Blood Purification for Improved Patient Care
Schlieren, Switzerland, August 24th 2023 – hemotune AG, a pioneering MedTech startup revolutionizing blood purification [...]
Continue reading
Clinical Development Press Release
hemotune AG initiates joint feasibility project on the HemoSystem with AstraZeneca
Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for [...]
Continue reading
Clinical Development Innovation Press Release
At the forefront of research into prevention of scar tissue formation after a heart attack
Resistell’s first patients recruited for international clinical study [...]
Continue reading
Clinical Development Innovation Press Release
Resistell’s first patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell’s first patients recruited for international clinical study [...]
Continue reading
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Collaboration, Press Release
More safety for seniors at home with a contactless fall detection solution
Big congratulations to Sedimentum, who has launched a contactless emergency product for Swiss
households: “SAFE-living”, the intelligent fall detection service. An innovative solution that
doesn’t require wearing a bracelet or pressing an emergency button.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Only six months after closing its seed round of CHF 2.1 million, the successful healthtech start-up closes its pre-series A financing round of CHF 3.3 million. With this new capital, Sedimentum intends to conquer the Swiss B2C market with its intelligent SAFE-living solution.
Last week we were honored to organize a Social Media workshop with the startup macu4 where we had a valuable conversation about how beneficial is to define e.g., your strategy, brand awareness, or target group to grow and accelerate your business.
Collaboration, Press Release
Resistell AG announces completion of clinical pilot Performance Evaluation Study
We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.
We’re delighted to announce a new collaboration between HEMEX and The Bioinformatics CRO which will provide an even more complete CRO service for our start-ups! Find out how this collaboration can support you throughout your Clinical Development phase.
Collaboration, Innovation, Press Release
Comms&Media service for startups powered by Benz Advisory, mediacrewgroup, and HEMEX
Benz Advisory, mediacrewgroup, and HEMEX join forces to support early-stage companies with strategic communications through a new service called Comms&Media. Targeted at early-stage businesses from all industries, it offers a unique, holistic approach to help companies develop and implement effective external and internal communications.
Resistell has started the Performance Evaluation Study (PES) of its groundbreaking nanomotion technology at Lausanne University Hospital. At HEMEX, are very happy to be part of this project, as we will be monitoring the clinical trial over the next 12 months.